Christopher Maulion, MD
Assistant Professor of Cardiovascular MedicineCards
About
Research
Publications
2026
Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure
Gupta D, Stevenson L, Garner E, Maulion C, Nian H, Wright P, Turcu A, Wei S, Brown N. Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure. Circulation Heart Failure 2026, 19: e014117. PMID: 42028604, PMCID: PMC13171156, DOI: 10.1161/circheartfailure.125.014117.Peer-Reviewed Original Research
2025
Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure
Rao V, Cox Z, Ivey-Miranda J, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Turner J, Wilson F, Shilpak M, Estrella M, Welling P, Wilcox C, Ellison D, Forbush B, Testani J. Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure. Journal Of The American Society Of Nephrology 2025, 37: 533-544. PMID: 40938670, PMCID: PMC12935386, DOI: 10.1681/asn.0000000887.Peer-Reviewed Original ResearchImpact of clinical pathways on enhancing compliance with evidence-based therapies for Heart failure with reduced ejection fraction–A retrospective cohort study
Kanaparthy N, Possick S, Teng W, Maulion C, Kim N. Impact of clinical pathways on enhancing compliance with evidence-based therapies for Heart failure with reduced ejection fraction–A retrospective cohort study. PLOS ONE 2025, 20: e0330188. PMID: 40906662, PMCID: PMC12410806, DOI: 10.1371/journal.pone.0330188.Peer-Reviewed Original ResearchHypertension after solid-organ transplantation: special considerations for management
Feliberti J, Alam A, Maulion C. Hypertension after solid-organ transplantation: special considerations for management. Current Opinion In Cardiology 2025, 40: 193-198. PMID: 40401425, DOI: 10.1097/hco.0000000000001230.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCirculating Tissue Specific Extracellular Vesicles for Noninvasive Monitoring of Acute Cellular Rejection in Clinical Heart Transplantation
Korutla L, Hu R, Liu Y, Romano C, Habertheuer A, Abedi P, Wang H, Molugu S, Rostami S, Naji A, Nuqali A, Beasley M, Maulion C, Hahn S, Ahmad T, Wang Z, Sen S, Vallabhajosyula P. Circulating Tissue Specific Extracellular Vesicles for Noninvasive Monitoring of Acute Cellular Rejection in Clinical Heart Transplantation. Transplantation 2025, 109: 1540-1550. PMID: 40238644, DOI: 10.1097/tp.0000000000005369.Peer-Reviewed Original ResearchFrom Prediction to Practice: Evaluating the Limitations of BAN ADHF Risk Score Against Natriuresis-Guided Diuresis
Maulion C, Feliberti J, Alam A. From Prediction to Practice: Evaluating the Limitations of BAN ADHF Risk Score Against Natriuresis-Guided Diuresis. The American Journal Of Cardiology 2025, 249: 83-84. PMID: 40068784, DOI: 10.1016/j.amjcard.2025.03.008.Commentaries, Editorials and Letters
2024
Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal
Asher J, Ivey-Miranda J, Maulion C, Cox Z, Borges-Vela J, Mendoza-Zavala G, Cigarroa-Lopez J, Silva-Rueda R, Revilla-Monsalve C, Moreno-Villagomez J, Ramos-Mastache D, Goedje O, Crosbie I, McIntyre C, Finkelstein F, Turner J, Testani J, Rao V. Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal. Kidney Medicine 2024, 7: 100938. PMID: 39790231, PMCID: PMC11714391, DOI: 10.1016/j.xkme.2024.100938.Peer-Reviewed Original ResearchMechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original Research
2023
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
IRB ID2000028712RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsErtugliflozin in Acute Heart Failure
IRB ID2000027951RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Clinical Care
Overview
Christopher Maulion, MD, is a cardiologist who specializes in advanced heart failure and transplant. He treats critically ill patients with cardiomyopathy, a spectrum of diseases of the heart muscle that lead to diminished heart function, potentially requiring advanced therapies including heart transplantation and left ventricular assist devices.
Dr. Maulion also is working with heart transplant surgeons to spearhead a multi-site clinical trial at Yale involving DCD (donation after cardiac death). Utilization of DCD organs is relatively new in the U.S., where the vast majority of donor hearts are retrieved as “donation after brain death.” Dr. Maulion reports, “DCD is the likely next chapter in cardiac transplantation,” and the trial may be the first step toward expanding the number of available organs and providing lifesaving opportunities for patients.
The heart failure and transplant field attracted Dr. Maulion because of its complexity and the opportunities it provides to help very sick patients get their lives back. “Advanced heart failure cardiology requires a broad knowledge base of not only cardiology but also internal medicine,” he says. “In addition, it is a field that is innovating in multiple fronts, spanning from the medical treatment of heart failure to mechanical circulatory support devices and heart transplant.” The work has also shaped his research interests in DCD heart transplantation, medical treatments in chronic heart failure, and cardiorenal syndrome, which involves both the heart and kidneys.
But Dr. Maulion says he is most grateful for the incredible patients he has met. “Overcoming the odds and being able to give a person a new lease on life is an amazing feeling,” he says. “Dealing with such a sick population has taught me how resilient a patient can be.”
Clinical Specialties
Fact Sheets
Congestive Heart Failure (CHF)
Learn More on Yale MedicineVentricular Assist Device (VAD)
Learn More on Yale MedicineHeart Failure Surgery
Learn More on Yale MedicineHeart Transplant
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
News
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.